The purpose of this study is to collect epidemiological and clinical data to assess the vaccine impact and occurrence of confirmed acute hepatitis A cases in sentinel hospitals after the introduction of Havrix™ into the Expanded Program of Immunization.
This is an observational, prospective, multi-centre, sentinel based study in 3 hospitals in Panama. Hospitals are selected based on population density or hepatitis A disease burden. The Pan American Health Organization (PAHO) definition for a possible case of acute hepatitis A are used for subjects aged between \>1 month and \<15 years. Data regarding clinical and epidemiologic information are collected and serum samples are collected to test hepatitis A markers and determine if infection with hepatitis A virus has recently occurred. Surveillance will be for a period of approximately 2.5 years from the date of study initiation.
Study Type
OBSERVATIONAL
Enrollment
42
Serum samples collected
GSK Investigational Site
Clayton, Provincia de Panamá, Panama
Occurrence of confirmed acute hepatitis A cases identified in the selected sentinel hospitals during the study period by age group, area of residence and year of surveillance
Time frame: average time-frame: 2.5 years
Occurrence of possible and probable cases of acute hepatitis A virus by age group, area of residence and year of surveillance
Time frame: average time-frame: 2.5 years
Risk factors for confirmed cases of acute hepatitis A
Time frame: average time-frame: 2.5 years
Frequency of different clinical signs and symptoms of hepatitis A
Time frame: average time-frame: 2.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.